ValuEngine upgraded shares of Icon (NASDAQ:ICLR) from a hold rating to a buy rating in a report released on Sunday.

A number of other brokerages have also weighed in on ICLR. Zacks Investment Research upgraded shares of Icon from a sell rating to a hold rating and set a $128.00 price objective for the company in a report on Wednesday, October 11th. SunTrust Banks reiterated a buy rating and set a $138.00 price objective on shares of Icon in a report on Sunday, October 29th. Credit Suisse Group reiterated an outperform rating and set a $120.00 price objective (up previously from $105.00) on shares of Icon in a report on Monday, October 16th. Robert W. Baird reiterated a buy rating and set a $123.00 price objective on shares of Icon in a report on Thursday, October 12th. Finally, KeyCorp reiterated an overweight rating and set a $125.00 price objective (up previously from $115.00) on shares of Icon in a report on Monday, November 13th. They noted that the move was a valuation call. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $120.91.

Shares of Icon (NASDAQ:ICLR) opened at $112.15 on Friday. Icon has a twelve month low of $74.30 and a twelve month high of $124.48. The firm has a market cap of $6,073.15, a PE ratio of 21.73, a P/E/G ratio of 1.73 and a beta of 0.56. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.32 by $0.03. Icon had a net margin of 16.37% and a return on equity of 28.42%. The company had revenue of $440.30 million during the quarter, compared to analyst estimates of $438.09 million. During the same quarter last year, the business posted $1.19 EPS. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. equities analysts forecast that Icon will post 5.37 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of ICLR. Schwab Charles Investment Management Inc. raised its holdings in shares of Icon by 39.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 16,713 shares of the medical research company’s stock valued at $1,635,000 after purchasing an additional 4,692 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Icon by 0.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 312,735 shares of the medical research company’s stock valued at $30,582,000 after purchasing an additional 1,947 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Icon by 35.9% in the 2nd quarter. Legal & General Group Plc now owns 7,592 shares of the medical research company’s stock valued at $743,000 after purchasing an additional 2,006 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Icon by 16.8% in the 2nd quarter. Principal Financial Group Inc. now owns 448,115 shares of the medical research company’s stock valued at $43,821,000 after purchasing an additional 64,456 shares in the last quarter. Finally, Cipher Capital LP raised its holdings in shares of Icon by 41.3% in the 2nd quarter. Cipher Capital LP now owns 9,601 shares of the medical research company’s stock valued at $939,000 after purchasing an additional 2,806 shares in the last quarter. Institutional investors and hedge funds own 89.66% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Icon (ICLR) Upgraded to “Buy” at ValuEngine” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/01/01/icon-iclr-upgraded-to-buy-at-valuengine.html.

About Icon

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Stock Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related stocks with our FREE daily email newsletter.